Opinion

Video

Key Takeaways From an Indirect Comparison of ENZA and DARO in mHSPC

A panelist discusses how both the ARCHES and ARANOTE trials demonstrated significant improvements in radiographic progression-free survival with their respective novel hormonal therapies (enzalutamide in ARCHES and apalutamide in ARANOTE) when added to androgen deprivation therapy (ADT) for metastatic hormone-sensitive prostate cancer, with consistent benefits observed across key subgroups and generally manageable safety profiles.

Summary for Physicians: ARCHES and ARANOTE Trial Outcomes

Both the ARCHES and ARANOTE trials demonstrated significant clinical benefits when adding novel hormonal therapies to ADT for metastatic hormone-sensitive prostate cancer:

  • ARCHES (enzalutamide + ADT): Significant improvement in radiographic progression-free survival
  • ARANOTE (apalutamide + ADT): Significant improvement in radiographic progression-free survival

Key findings across both trials:

  • Consistent benefits observed across major patient subgroups
  • Generally manageable safety profiles

These results support the addition of novel hormonal agents to ADT in the management of metastatic hormone-sensitive prostate cancer.

Related Videos
1 expert is featured in this series.
1 expert is featured in this series.
1 expert is featured in this series.
1 expert is featured in this series.
1 expert is featured in this series.
1 expert is featured in this series.
1 expert is featured in this series.
1 expert is featured in this series.
1 expert is featured in this series.
Related Content
© 2025 MJH Life Sciences

All rights reserved.